Last reviewed · How we verify
Abacavir/lamivudine and efavirenz
Abacavir/lamivudine and efavirenz is a Antiretroviral combination therapy (NRTI + NNRTI) Small molecule drug developed by GlaxoSmithKline. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced patients.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing the virus from copying its genetic material and integrating into host cells. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.
At a glance
| Generic name | Abacavir/lamivudine and efavirenz |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Antiretroviral combination therapy (NRTI + NNRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that compete with natural nucleotides to block HIV reverse transcriptase, while efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that directly binds and inhibits the same enzyme through a different mechanism. Together, these three agents provide complementary inhibition of viral replication at a critical step in the HIV life cycle.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
Common side effects
- Dizziness
- Headache
- Nausea
- Rash
- Abacavir hypersensitivity reaction
- CNS effects (neuropsychiatric)
- Elevated liver enzymes
- Lipid abnormalities
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Research on the Psychological Status of Patients With HIV-1 Infection
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio (PHASE3)
- The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy (PHASE2)
- Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children (PHASE2, PHASE3)
- Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abacavir/lamivudine and efavirenz CI brief — competitive landscape report
- Abacavir/lamivudine and efavirenz updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about Abacavir/lamivudine and efavirenz
What is Abacavir/lamivudine and efavirenz?
How does Abacavir/lamivudine and efavirenz work?
What is Abacavir/lamivudine and efavirenz used for?
Who makes Abacavir/lamivudine and efavirenz?
What drug class is Abacavir/lamivudine and efavirenz in?
What development phase is Abacavir/lamivudine and efavirenz in?
What are the side effects of Abacavir/lamivudine and efavirenz?
What does Abacavir/lamivudine and efavirenz target?
Related
- Drug class: All Antiretroviral combination therapy (NRTI + NNRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: GlaxoSmithKline — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced patients
- Compare: Abacavir/lamivudine and efavirenz vs similar drugs
- Pricing: Abacavir/lamivudine and efavirenz cost, discount & access